ABOUT US

A team building genomic platforms safely & responsibly

GenomeArc is a team of scientists and engineers dedicated to solving the most complex computational challenges in multi-omics and large-scale genomic cohorts accelerating diagnostics and unlocking deep therapeutic insights.

Request access Read case studies
Our Vision

We live in a transformative era where clinical genomics and artificial intelligence are converging to redefine the boundaries of human health. The integration of multimodal AI and ultimately artificial general intelligence holds the potential to drive one of the greatest shifts in medical history, moving us from generalized treatments to true precision medicine.

At GenomeArc, we are committed to advancing science and transforming clinical workflows to improve the lives of billions.

Our Mission

To serve diverse communities through foundational resources like the Arab Pangenome Reference, ensuring that the benefits of genomic discovery reach every population.

37
Populations represented
50+
Institutions user

“This is great testament to GenomeArc’s commitment to quality assurance. At GenomeArc, we believe in building technology that can help human lives with precision healthcare solution.”

Mohammed Uddin, PhD Founder and CEO, GenomeArc
Founder & Scientific Advisory Board
Mohammed Uddin (Dafil), PhD
Founder and CEO
Mohammed Uddin (Dafil), PhD
Founder and CEO
GenomeArc Inc., Toronto
Scientific Advisory Board
Marc Woodbury-Smith
MD, PhD
Senior Lecturer, Biosciences Institute
Newcastle University, Newcastle Upon Tyne, UK
Bakhrom K. Berdiev
MD, PhD
Associate Professor, College of Medicine
Mohammed Bin Rashid University, Dubai
Proton Rahman
MD, FRCPC, FCAHC
Professor of Medicine, Faculty of Medicine
Memorial University, Canada
Wolfgang Kuebler
MD, PhD
Director, Institute of Physiology
Charité — Universitätsmedizin Berlin
Professor and Associate Scientist
University of Toronto
Our Journey

From 2021 to billions of lives

2021
Founded
GenomeArc begins, fueled by the ambitious goal of using advanced technology to support patients facing cancer and rare diseases.
2022
Horizon Development Begins
Despite a global pandemic delaying our initial launch, the team perseveres beginning development on our flagship tertiary analysis platform.
2023
First Horizon Release
Officially released a major milestone in providing sophisticated clinical genomic solutions.
2024
Horizon Intelligence
Multimodal AI introduced to enhance diagnostic training and database accuracy.
2026
Horizon 2026 & Open science
The most mature version yet. We launch a free, open-access variant search server for the global research community.